1. Academic Validation
  2. Activation of nicotinamide adenine dinucleotide phosphate oxidase is the primary trigger of epileptic seizures in rodent models

Activation of nicotinamide adenine dinucleotide phosphate oxidase is the primary trigger of epileptic seizures in rodent models

  • Ann Neurol. 2019 Jun;85(6):907-920. doi: 10.1002/ana.25474.
Anton Malkov 1 2 Anton I Ivanov 1 Alexandra Latyshkova 2 Piotr Bregestovski 1 3 Misha Zilberter 4 Yuri Zilberter 1
Affiliations

Affiliations

  • 1 Aix-Marseille University, National Institute of Health and Medical Research, Institute of Neuroscience Systems, Mixed Unit of Research 1106, Marseille, France.
  • 2 Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, Pushchino, Russia.
  • 3 Institute of Neurosciences, Kazan State Medical University, Kazan, Russia.
  • 4 Gladstone Institute of Neurological Disease, San Francisco, CA.
Abstract

Objective: Despite decades of epilepsy research, 30% of focal epilepsies remain resistant to antiseizure drugs, with effective drug development impeded by lack of understanding on how seizures are initiated. Here, we report the mechanism of seizure onset relevant to most seizures that are characteristic of focal epilepsies.

Methods: Electric and metabolic network parameters were measured using several seizure models in mouse hippocampal slices and acutely induced seizures in rats in vivo to determine metabolic events occurring at seizure onset.

Results: We show that seizure onset is associated with a rapid release of H2 O2 resulting from N-methyl-D-aspartate (NMDA) receptor-mediated activation of nicotinamide adenine dinucleotide phosphate oxidase (NOX). NOX blockade prevented the fast H2 O2 release as well as the direct current shift and seizurelike event induction in slices. Similarly, intracerebroventricular injection of NOX antagonists prevented acutely induced seizures in rats.

Interpretation: Our results show that seizures are initiated by NMDA receptor-mediated NOX-induced oxidative stress and can be arrested by NOX inhibition. We introduce a novel use for blood-brain barrier-permeable NOX inhibitor with a significant potential to become the first seizure-specific medication. Thus, targeting NOX may provide a breakthrough treatment for focal epilepsies. ANN NEUROL 2019;85:907-920.

Figures
Products